Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02136186 · ClinicalTrials.gov registry record · NA
Home Telemonitoring in Patients at High Risk for Readmission
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 1,380
- Enrollment target
NCT02136186: Completed NA study, sponsored by Mayo Clinic.
NCT02136186 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 1,380 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02136186, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,380 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of home telemonitoring as an intervention to decrease hospital readmissions in patients at high risk for readmission. The overall readmission rate for high-risk MCF hospital patients is approximately 20%. Currently a system is in place to identify and score all MCF patients for their risk of readmission. This score is based on multiple variables including but not limited to: co-morbid conditions, patient's health literacy, whether they are a Medicare/Medicaid patient, their in-home social support, and whether they have had prior hospital admissions within the previous year. The literature shows that home telemonitoring of patients has had mixed results for effectiveness at preventing hospitalizations and emergency department visits. Many of these reports have restricted studies to patients with specific diseases or general characteristics; some have shown improved results while others have not. No study has examined patients who are high risk for readmission to determine if home telemonitoring for 30 days post-discharge reduces the risk for 30-day readmission.
Primary Outcome
Compare 30-day readmission rates between high-risk patients who are home monitored using technology and high-risk patients who receive the current standard care.
Interventions
- DEVICE Philips Telehealth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,380 participants |
| Start Date | 2014-10 |
| Est. Completion | 2020-07-31 |
| Phase | NA |
What the finished NCT02136186 record still lists
NCT02136186 is an interventional study that assigns participants to a tested intervention. Its 1,380 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Philips Telehealth is the first listed.
NCT02136186 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02136186 about?
NCT02136186 is a clinical study titled "Home Telemonitoring in Patients at High Risk for Readmission". This study will evaluate the efficacy of home telemonitoring as an intervention to decrease hospital readmissions in patients at high risk for readmission. The overall readmission rate for high-risk MCF hospital patients is approximately 20%. Currently a system is in place to identify and score all ...
What is the current status of trial NCT02136186?
This trial is currently completed. It is a NA study. The enrollment target is 1,380 participants. The study started on 2014-10. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT02136186?
The interventions under investigation include: Philips Telehealth (DEVICE).
Who is sponsoring clinical trial NCT02136186?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02136186's enrollment target sits among peer trials
1,380 73rd of 2000 higher than 1,928 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT05006131 · 1,395 participants
Pancreatic Cancer Screening for At-risk Individuals
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia